Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8 + T-cell response in allogeneic stem cell transplant recipients

Clinical and Vaccine Immunology

Volumn 19, Issue 5, 2012, Pages 791-796

  Clari, María Ángeles ^a   Munoz Cobo, Beatriz ^a   Carlos Solano, ^a,b   Benet, Isabel ^a,b   Costa, Elisa ^a   Remigia, María José ^a   Bravo, Dayana ^a   Amat, Paula ^a   Navarro, David ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GANCICLOVIR; HLA ANTIGEN CLASS 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FLOW CYTOMETRY; GENOTYPE; GRAFT RECIPIENT; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERMETHOD COMPARISON; MALE; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SEROLOGY; VIRUS DETECTION;

ADULT; AGED; CD8-POSITIVE T-LYMPHOCYTES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; STEM CELL TRANSPLANTATION; TRANSPLANTATION;

EID: 84860346013     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05633-11     Document Type: Article

References (19)

1. Avetisyan G, Aschan J, Hägglund H, Ringdén O, Ljungman P. 2007. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant. 40:865-869. (Pubitemid 350020321)
2. Fleming T, Dunne J, Crowley B. 2010. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-cell responses using the Quanti-FERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. J. Med. Virol. 82:433-440.
3. Gimeno C, et al. 2008. Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. J. Clin. Microbiol. 46: 3311-3318.
4. Giulieri S, Manuel O. 2011. QuantiFERON-CMV assay for the assessment of cytomegalovirus cell-mediated immunity. Expert Rev. Mol. Diagn. 11:17-25.
5. Kumar D, et al. 2009. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am. J. Transplant. 9:1214-1222.
6. Lacey S, et al. 2006. Functional comparison of T cells recognizing cytomegalovirus pp65 and immediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. J. Infect. Dis. 194:1410-1421. (Pubitemid 44706510)
7. Ljungman P. 2006. Would monitoring CMV immune responses allow improved control of CMV in stem cell transplant patients. J. Clin. Virol. 35:493-495. (Pubitemid 43324854)
8. Lochmanova A, et al. 2010. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation. Transplant. Proc. 42:3574-3577.
9. + T cells and kinetics of NKG2C+ NK cells associated with the resolution of CMV DNAemia in allogeneic stem cell transplant recipients. J. Med. Virol. 84:259-267.
10. + T cells protect against high-level replication after liver transplantation. Am. J. Transplant. 8:2590-2599.
11. + T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection. Haematologica 93:1434-1436.
12. Solano C, et al. 2011. Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic stem-cell transplant recipients: A pilot experience. Transplantation 92:e17-e20.
13. Solano C, Navarro D. 2010. Clinical virology of cytomegalovirus infection following hematopoietic transplantation. Future Virol. 5:111-124.
14. Tormo N, et al. 17 January 2011, posting date. Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8(+) and CD4(+) T-cell responses affording protection fromCMVDNAemia following allogeneic hematopoietic SCT. Bone Marrow Transplant. [Epub ahead of print.] doi:10.1038/ bmt.2010.330.
15. + T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 45:543-549.
16. Tormo N, et al. 2010. Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgammaCD8+ andCD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: Potential implications for the management of active CMV infection. J. Med. Virol. 82: 1208-1215.
17. + T-cell responses using QuantiFERON-CMV. Transpl. Infect. Dis. 9:165-170. (Pubitemid 46669086)
18. + T-cell immunity. Am. J. Transplant. 8:1749-1754.
19. Zhou W, et al. 2009. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 113:6465-6476.